[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-001", "question": "A 6-year-old boy with a history of Diamond-Blackfan anemia (DBA) treated with chronic corticosteroids and transfusions presents with progressive dyspnea and fatigue. Echocardiography reveals a restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. Genetic testing confirms a pathogenic variant in RPS19. Which of the following is the most appropriate next step in management?", "options": ["Initiation of high-dose beta-blockers and ACE inhibitors", "Referral for combined heart-lung transplantation evaluation", "Immediate discontinuation of corticosteroids and transition to defibrotide", "Addition of L-leucine supplementation to current regimen", "Cardiac MRI with T1 mapping and extracellular volume quantification"], "answer": "D", "answer_index": 3, "explanation": "Diamond-Blackfan anemia is associated with ribosomal protein mutations, and L-leucine has been shown to improve ribosomal function and hematopoiesis in DBA. In patients with DBA-associated cardiomyopathy, addressing the underlying ribosomal dysfunction with leucine supplementation may improve cardiac function, whereas conventional heart failure therapies are less effective for this specific pathophysiology. Beta-blockers/ACE inhibitors would be insufficient, transplantation is premature without addressing the underlying metabolic defect, defibrotide is for hepatic veno-occlusive disease, and advanced imaging would not change management.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: K (miskeyed). Secondary: U (underspecified). The vignette describes a 6-year-old with DBA, chronic steroids/transfusions, and new restrictive cardiomyopathy with severe diastolic dysfunction and moderate pulmonary hypertension. The key asks for the next management step. The correct answer should address the cardiomyopathy, likely due to iron overload or DBA-related fibrosis. The only option that directly evaluates myocardial tissue and iron content is E (cardiac MRI with T1 mapping), which is the most appropriate next step to guide therapy. Options A and B are premature or potentially harmful; C is irrelevant; D (L‑leucine) is unsupported for cardiac disease and misstates that conventional HF therapy is ineffective. The explanation incorrectly claims L‑leucine improves cardiac function, contradicting current consensus. Thus the item is miskeyed. The stem also lacks clarity on whether the cardiomyopathy is primarily iron‑mediated or primary DBA‑related, making it underspecified. Minimal fix: replace option D with a standard therapy (e.g., intensify chelation or start diuretics) and re‑key to E, or revise the stem to indicate iron overload and key to chelation.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed). Secondary: U (underspecified). The vignette describes a 6-year-old with DBA, chronic steroids/transfusions, and new restrictive cardiomyopathy with severe diastolic dysfunction and moderate pulmonary hypertension. The key asks for the next management step. The correct answer should address the cardiomyopathy, likely due to iron overload or DBA-related fibrosis. The only option that directly evaluates myocardial tissue and iron content is E (cardiac MRI with T1 mapping), which is the most appropriate next step to guide therapy. Options A and B are premature or potentially harmful; C is irrelevant; D (L‑leucine) is unsupported for cardiac disease and misstates that conventional HF therapy is ineffective. The explanation incorrectly claims L‑leucine improves cardiac function, contradicting current consensus. Thus the item is miskeyed. The stem also lacks clarity on whether the cardiomyopathy is primarily iron‑mediated or primary DBA‑related, making it underspecified. Minimal fix: replace option D with a standard therapy (e.g., intensify chelation or start diuretics) and re‑key to E, or revise the stem to indicate iron overload and key to chelation.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-002", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe hypertension (200/120 mmHg), headache, and visual disturbances. Laboratory studies show thrombocytopenia (platelets 85,000/μL), elevated liver enzymes (AST 250 U/L, ALT 280 U/L), and creatinine 1.8 mg/dL. Magnesium sulfate is initiated. Despite aggressive antihypertensive therapy with labetalol and hydralazine, her blood pressure remains persistently elevated. Which of the following is the most appropriate next pharmacologic intervention?", "options": ["Immediate initiation of nitroprusside infusion", "Addition of oral nifedipine XL 30 mg daily", "Intravenous fenoldopam infusion titrated to effect", "Sublingual captopril 12.5 mg repeated every 30 minutes", "Intravenous esmolol bolus followed by continuous infusion"], "answer": "C", "answer_index": 2, "explanation": "Fenoldopam is a dopamine-1 receptor agonist that causes vasodilation without compromising uteroplacental blood flow and is safe in pregnancy for refractory hypertension. Nitroprusside is contraindicated due to risk of cyanide toxicity to the fetus. Nifedipine XL has slow onset and is inadequate for acute control. ACE inhibitors like captopril are contraindicated in pregnancy due to fetal renal toxicity. Esmolol may cause fetal bradycardia and is less ideal than fenoldopam for pregnancy-associated hypertensive emergencies.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: K (Miskeyed). The stem presents severe preeclampsia with hypertension refractory to first-line IV agents labetalol and hydralazine. While the rationale correctly excludes nitroprusside (fetal cyanide toxicity), nifedipine XL (slow onset unsuitable for emergency), captopril (ACE inhibitor contraindicated), and esmolol (fetal bradycardia risk), it fundamentally errs by endorsing fenoldopam as 'most appropriate.' Major obstetric and cardiology guidelines (ACOG, AHA) do not recommend fenoldopam in pregnancy; evidence for safety and efficacy is lacking. Standard next steps include optimizing current IV therapy, adding oral immediate-release nifedipine, or initiating IV nitroglycerin. Fenoldopam is not considered a preferred or even standard alternative agent. Thus, the item is miskeyed—a guideline-concordant answer exists, but the key does not match it. Medical accuracy score is 2 due to this substantive teaching error that misleads learners. Minimal fix: Replace option C with 'Intravenous nitroglycerin infusion titrated to effect' and key this option, reflecting accepted management of refractory severe hypertension in preeclampsia.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). The stem presents severe preeclampsia with hypertension refractory to first-line IV agents labetalol and hydralazine. While the rationale correctly excludes nitroprusside (fetal cyanide toxicity), nifedipine XL (slow onset unsuitable for emergency), captopril (ACE inhibitor contraindicated), and esmolol (fetal bradycardia risk), it fundamentally errs by endorsing fenoldopam as 'most appropriate.' Major obstetric and cardiology guidelines (ACOG, AHA) do not recommend fenoldopam in pregnancy; evidence for safety and efficacy is lacking. Standard next steps include optimizing current IV therapy, adding oral immediate-release nifedipine, or initiating IV nitroglycerin. Fenoldopam is not considered a preferred or even standard alternative agent. Thus, the item is miskeyed—a guideline-concordant answer exists, but the key does not match it. Medical accuracy score is 2 due to this substantive teaching error that misleads learners. Minimal fix: Replace option C with 'Intravenous nitroglycerin infusion titrated to effect' and key this option, reflecting accepted management of refractory severe hypertension in preeclampsia.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-003", "question": "A 58-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab combination therapy presents with acute respiratory failure requiring mechanical ventilation. Bronchoalveolar lavage shows lymphocytic predominance without infectious organisms. High-dose methylprednisolone (2 mg/kg/day) was initiated 72 hours ago without improvement. Which of the following is the most appropriate next step in management?", "options": ["Add infliximab 5 mg/kg single dose", "Initiate cyclophosphamide 1 g/m² IV", "Switch to dexamethasone 40 mg daily", "Begin plasma exchange therapy", "Add tocilizumab 8 mg/kg IV"], "answer": "A", "answer_index": 0, "explanation": "For steroid-refractory immune checkpoint inhibitor-related pneumonitis, TNF-alpha inhibition with infliximab is the recommended next-line therapy based on retrospective evidence showing improved outcomes. Cyclophosphamide is used for other immune-related adverse events like myocarditis but not first-line for pneumonitis. Switching corticosteroids is unlikely to help if already on high-dose methylprednisolone. Plasma exchange is not established for this condition. Tocilizumab (IL-6 inhibitor) is used for cytokine release syndrome but not specifically for checkpoint inhibitor pneumonitis.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V (Valid). Verdict on keyed answer: Correct best answer. The stem presents classic steroid-refractory immune checkpoint inhibitor (ICI)-related pneumonitis: metastatic RCC on nivolumab/ipilimumab, acute respiratory failure, lymphocytic BAL without organisms, and no improvement after 72 hours of high-dose methylprednisolone. These clues point unequivocally to need for second-line immunosuppression. Among the choices, infliximab is uniquely defensible—major guidelines (NCCN, ASCO) endorse TNF-alpha inhibition for steroid-refractory ICI pneumonitis based on retrospective evidence. The distractors are appropriately eliminated: cyclophosphamide is first-line for myocarditis, not pneumonitis; switching steroids is ineffective after high-dose failure; plasma exchange lacks established efficacy; tocilizumab is for cytokine release syndrome. No internal contradictions exist, and options permit clear discrimination. Medical accuracy is high (score 4) though slightly simplified: guidelines also list mycophenolate mofetil as an alternative, and infliximab carries infection risk in ventilated patients. This nuance is omitted but doesn't invalidate the item. Minimal fix: Add phrase 'in the absence of active infection' to stem, or include mycophenolate mofetil as an option to reflect guideline alternatives.\",\n\"medical_accuracy_score\": 4,\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict on keyed answer: Correct best answer. The stem presents classic steroid-refractory immune checkpoint inhibitor (ICI)-related pneumonitis: metastatic RCC on nivolumab/ipilimumab, acute respiratory failure, lymphocytic BAL without organisms, and no improvement after 72 hours of high-dose methylprednisolone. These clues point unequivocally to need for second-line immunosuppression. Among the choices, infliximab is uniquely defensible—major guidelines (NCCN, ASCO) endorse TNF-alpha inhibition for steroid-refractory ICI pneumonitis based on retrospective evidence. The distractors are appropriately eliminated: cyclophosphamide is first-line for myocarditis, not pneumonitis; switching steroids is ineffective after high-dose failure; plasma exchange lacks established efficacy; tocilizumab is for cytokine release syndrome. No internal contradictions exist, and options permit clear discrimination. Medical accuracy is high (score 4) though slightly simplified: guidelines also list mycophenolate mofetil as an alternative, and infliximab carries infection risk in ventilated patients. This nuance is omitted but doesn't invalidate the item. Minimal fix: Add phrase 'in the absence of active infection' to stem, or include mycophenolate mofetil as an option to reflect guideline alternatives.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-004", "question": "A 3-day-old term neonate presents with poor feeding, lethargy, and hypoglycemia (glucose 25 mg/dL). Physical exam reveals macroglossia, umbilical hernia, and mild hepatomegaly. Newborn screening shows elevated galactose and galactitol. Which of the following additional findings would be most specific for confirming the diagnosis?", "options": ["Elevated serum ammonia level", "Absent reducing substances in urine after lactose challenge", "Normal glycogen content on liver biopsy", "Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes", "Presence of cataract on ophthalmologic examination"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests galactosemia, but the key distinguishing feature is that in galactose epimerase deficiency (a rare form), liver biopsy shows normal glycogen content, whereas in classic galactosemia (GALT deficiency), glycogen is depleted. Elevated ammonia suggests urea cycle defect. Absent reducing substances would argue against galactosemia. GALT enzyme deficiency confirms classic galactosemia, not the epimerase variant. Cataracts occur in both forms and are not specific.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: K (miskeyed). The vignette describes a neonate with hypoglycemia, macroglossia, umbilical hernia, hepatomegaly, and elevated galactose/galactitol, suggesting a possible galactosemia. The most specific test for classic galactosemia is deficient GALT activity in erythrocytes (option D). Option C (normal liver glycogen) is not a standard diagnostic criterion for any galactosemia variant; the explanation’s claim that it distinguishes galactose epimerase deficiency is unsupported and not part of mainstream practice. The question is ambiguous about which galactosemia type is targeted, but the key does not match the best answer. The stem also includes features (macroglossia, umbilical hernia) more typical of Beckwith‑Wiedemann syndrome, which are irrelevant and misleading. Medical accuracy is compromised by a non‑evidence‑based answer key and confusing clinical clues. Logical validity fails because a single best answer exists (D) but the provided key is C. Minimal fix: Change the correct answer to D and, if the intent is to test epimerase deficiency, revise the stem to include specific clues (e.g., normal GALT activity) and replace option C with a recognized diagnostic test for that variant.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (miskeyed). The vignette describes a neonate with hypoglycemia, macroglossia, umbilical hernia, hepatomegaly, and elevated galactose/galactitol, suggesting a possible galactosemia. The most specific test for classic galactosemia is deficient GALT activity in erythrocytes (option D). Option C (normal liver glycogen) is not a standard diagnostic criterion for any galactosemia variant; the explanation’s claim that it distinguishes galactose epimerase deficiency is unsupported and not part of mainstream practice. The question is ambiguous about which galactosemia type is targeted, but the key does not match the best answer. The stem also includes features (macroglossia, umbilical hernia) more typical of Beckwith‑Wiedemann syndrome, which are irrelevant and misleading. Medical accuracy is compromised by a non‑evidence‑based answer key and confusing clinical clues. Logical validity fails because a single best answer exists (D) but the provided key is C. Minimal fix: Change the correct answer to D and, if the intent is to test epimerase deficiency, revise the stem to include specific clues (e.g., normal GALT activity) and replace option C with a recognized diagnostic test for that variant.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-005", "question": "A 42-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome on warfarin (INR 2.5-3.5) presents with acute right leg pain and swelling. Doppler ultrasound confirms extensive deep vein thrombosis despite therapeutic anticoagulation. Lupus anticoagulant is positive, and anti-β2-glycoprotein I antibodies are elevated. Which of the following management strategies is most appropriate?", "options": ["Switch to rivaroxaban 20 mg daily", "Increase warfarin target INR to 3.5-4.5", "Add hydroxychloroquine 400 mg daily to current regimen", "Initiate intravenous immunoglobulin 1 g/kg for two days", "Place an inferior vena cava filter"], "answer": "C", "answer_index": 2, "explanation": "In antiphospholipid syndrome with breakthrough thrombosis despite therapeutic warfarin, adding hydroxychloroquine has been shown to reduce thrombotic risk through multiple mechanisms including inhibition of platelet activation and neutralization of antiphospholipid antibodies. Direct oral anticoagulants like rivaroxaban are less effective in triple-positive APS. Higher INR targets increase bleeding risk without proven benefit. IVIG is reserved for catastrophic APS. IVC filters do not address the hypercoagulable state and increase long-term DVT risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V (valid). Verdict: The keyed answer (C) is the single best choice. Key stem clues: breakthrough DVT despite therapeutic warfarin, presence of lupus anticoagulant and anti‑β2‑glycoprotein I antibodies (implying triple‑positive APS), and the need for an adjunct that addresses the underlying hypercoagulable state. The other options are less appropriate: DOACs are inferior in triple‑positive APS (A), higher INR targets lack proven benefit and increase bleeding (B), IVIG is reserved for catastrophic APS (D), and IVC filters do not treat the hypercoagulable state (E). No internal contradictions or missing critical details prevent a unique best answer. Medical accuracy: The explanation aligns with current APS management guidelines; HCQ is a recognized adjunct for thrombosis prevention in APS, especially with SLE, while the statements about DOACs, INR targets, IVIG, and IVC filters are consistent with consensus. Minor nuance: the stem does not explicitly state triple‑positivity, but the combination of lupus anticoagulant and anti‑β2‑glycoprotein I strongly implies it. Minimal fix: Insert ‘triple‑positive’ in the stem to remove any ambiguity.\",\n\"medical_accuracy_score\": 4,\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (valid). Verdict: The keyed answer (C) is the single best choice. Key stem clues: breakthrough DVT despite therapeutic warfarin, presence of lupus anticoagulant and anti‑β2‑glycoprotein I antibodies (implying triple‑positive APS), and the need for an adjunct that addresses the underlying hypercoagulable state. The other options are less appropriate: DOACs are inferior in triple‑positive APS (A), higher INR targets lack proven benefit and increase bleeding (B), IVIG is reserved for catastrophic APS (D), and IVC filters do not treat the hypercoagulable state (E). No internal contradictions or missing critical details prevent a unique best answer. Medical accuracy: The explanation aligns with current APS management guidelines; HCQ is a recognized adjunct for thrombosis prevention in APS, especially with SLE, while the statements about DOACs, INR targets, IVIG, and IVC filters are consistent with consensus. Minor nuance: the stem does not explicitly state triple‑positivity, but the combination of lupus anticoagulant and anti‑β2‑glycoprotein I strongly implies it. Minimal fix: Insert ‘triple‑positive’ in the stem to remove any ambiguity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy defibrillator presents with recurrent appropriate shocks for ventricular tachycardia. He is on maximally tolerated doses of carvedilol, lisinopril, and spironolactone. Amiodarone was started but discontinued due to thyroid toxicity. Which of the following is the most appropriate next antiarrhythmic therapy?", "options": ["Mexiletine 200 mg three times daily", "Sotalol 80 mg twice daily", "Dofetilide 500 mcg twice daily with inpatient initiation", "Ranolazine 1000 mg twice daily", "Propafenone 150 mg three times daily"], "answer": "C", "answer_index": 2, "explanation": "Dofetilide is a class III antiarrhythmic that is effective for ventricular tachycardia in structural heart disease and does not have the non-cardiac toxicity profile of amiodarone. It requires inpatient initiation due to risk of torsades de pointes. Mexiletine has limited efficacy as monotherapy. Sotalol is contraindicated in severe systolic dysfunction. Ranolazine has antianginal but limited antiarrhythmic evidence for VT. Propafenone is contraindicated in structural heart disease due to proarrhythmic risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: K (Miskeyed). The stem describes recurrent VT in severe ischemic cardiomyopathy (EF 25%) after amiodarone toxicity, prompting selection of an alternative antiarrhythmic. The keyed answer C (dofetilide) is medically inaccurate—dofetilide is indicated for atrial fibrillation, not ventricular tachycardia, and lacks established efficacy for VT suppression. While the rationale correctly eliminates sotalol and propafenone (contraindicated in structural heart disease) and ranolazine (no VT data), it falsely attributes VT efficacy to dofetilide. Mexiletine (Option A) is the only non-contraindicated option with recognized, albeit limited, utility in VT management, making it the sole defensible choice among those provided. The item is therefore miskeyed. Medical accuracy is compromised by this major factual error regarding dofetilide's indication. Minimal fix: Rekey to A and revise rationale to acknowledge mexiletine's modest efficacy as the only safe pharmacologic option; ideally, replace the question with a more clinically relevant scenario such as catheter ablation versus medical therapy for drug-refractory VT.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). The stem describes recurrent VT in severe ischemic cardiomyopathy (EF 25%) after amiodarone toxicity, prompting selection of an alternative antiarrhythmic. The keyed answer C (dofetilide) is medically inaccurate—dofetilide is indicated for atrial fibrillation, not ventricular tachycardia, and lacks established efficacy for VT suppression. While the rationale correctly eliminates sotalol and propafenone (contraindicated in structural heart disease) and ranolazine (no VT data), it falsely attributes VT efficacy to dofetilide. Mexiletine (Option A) is the only non-contraindicated option with recognized, albeit limited, utility in VT management, making it the sole defensible choice among those provided. The item is therefore miskeyed. Medical accuracy is compromised by this major factual error regarding dofetilide's indication. Minimal fix: Rekey to A and revise rationale to acknowledge mexiletine's modest efficacy as the only safe pharmacologic option; ideally, replace the question with a more clinically relevant scenario such as catheter ablation versus medical therapy for drug-refractory VT.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-007", "question": "A 28-year-old primigravida at 36 weeks gestation presents with progressive dyspnea and orthopnea. Echocardiography shows peripartum cardiomyopathy with LVEF 30%. After diuresis with furosemide, she remains symptomatic. Which of the following medications should be avoided until after delivery?", "options": ["Digoxin 0.125 mg daily", "Hydralazine 25 mg three times daily", "Isosorbide dinitrate 20 mg three times daily", "Sacubitril/valsartan 24/26 mg twice daily", "Metoprolol succinate 25 mg daily"], "answer": "D", "answer_index": 3, "explanation": "Sacubitril/valsartan contains an ARB (valsartan) which is contraindicated in pregnancy due to fetal renal toxicity and oligohydramnios risk, particularly in the third trimester. Digoxin, hydralazine, isosorbide dinitrate, and metoprolol are all acceptable in pregnancy for heart failure management. While ACE inhibitors and ARBs are absolutely contraindicated, the other medications listed can be used with appropriate monitoring.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). This item presents a third-trimester patient (36 weeks) with peripartum cardiomyopathy (LVEF 30%) who remains symptomatic after diuresis. The clinical problem is identifying a contraindicated medication during pregnancy. The key discriminating factor is absolute fetal safety: sacubitril/valsartan contains valsartan, an ARB that is strictly contraindicated in pregnancy, particularly in the second and third trimesters, due to established risks of fetal renal dysplasia, oligohydramnios, pulmonary hypoplasia, and fetal death. The keyed answer D is correct and uniquely defensible. All alternatives are pregnancy-compatible: digoxin is safe with decades of gestational use; hydralazine and isosorbide dinitrate are recommended vasodilators for heart failure and hypertension in pregnancy; metoprolol is a first-line beta-blocker with reassuring safety data. No internal contradictions exist, and the options permit unambiguous discrimination. Medical accuracy is gold-standard, fully consistent with FDA pregnancy labeling, ACC/AHA heart failure guidelines, and ACOG recommendations. The item tests a critical high-yield concept for obstetric cardiology. No revision needed.\",\"medical_accuracy_score\":5,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). This item presents a third-trimester patient (36 weeks) with peripartum cardiomyopathy (LVEF 30%) who remains symptomatic after diuresis. The clinical problem is identifying a contraindicated medication during pregnancy. The key discriminating factor is absolute fetal safety: sacubitril/valsartan contains valsartan, an ARB that is strictly contraindicated in pregnancy, particularly in the second and third trimesters, due to established risks of fetal renal dysplasia, oligohydramnios, pulmonary hypoplasia, and fetal death. The keyed answer D is correct and uniquely defensible. All alternatives are pregnancy-compatible: digoxin is safe with decades of gestational use; hydralazine and isosorbide dinitrate are recommended vasodilators for heart failure and hypertension in pregnancy; metoprolol is a first-line beta-blocker with reassuring safety data. No internal contradictions exist, and the options permit unambiguous discrimination. Medical accuracy is gold-standard, fully consistent with FDA pregnancy labeling, ACC/AHA heart failure guidelines, and ACOG recommendations. The item tests a critical high-yield concept for obstetric cardiology. No revision needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-008", "question": "A 5-year-old girl with history of recurrent sinopulmonary infections presents with new-onset ataxia and nystagmus. MRI brain shows diffuse cerebellar atrophy. Serum immunoglobulin levels reveal IgG 450 mg/dL, IgA 10 mg/dL, and IgM 15 mg/dL. Flow cytometry shows absent B cells. Which of the following genetic mutations is most likely responsible for this clinical presentation?", "options": ["BTK gene mutation", "CD40 ligand deficiency", "AICDA gene mutation", "RAG1 gene mutation", "ATM gene mutation"], "answer": "E", "answer_index": 4, "explanation": "Ataxia-telangiectasia (ATM gene mutation) presents with combined immunodeficiency (low immunoglobulins, absent B cells), recurrent infections, cerebellar ataxia, and oculomotor apraxia. BTK mutation causes X-linked agammaglobulinemia with absent B cells but no ataxia. CD40 ligand deficiency causes hyper-IgM syndrome with normal or increased IgM. AICDA mutation causes hyper-IgM syndrome type 2. RAG1 mutation causes severe combined immunodeficiency (SCID) but not typically with cerebellar atrophy.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"The vignette describes a 5‑year‑old with recurrent sinopulmonary infections, new‑onset ataxia, nystagmus, diffuse cerebellar atrophy, low IgG/IgA/IgM, and absent B cells. The key discriminating features are the combination of cerebellar neurodegeneration and combined immunodeficiency. The only option that explains both neurologic and immunologic findings is ATM (ataxia‑telangiectasia). However, the vignette’s statement that flow cytometry shows absent B cells is inaccurate; A‑T patients typically have normal B‑cell numbers with impaired class‑switch recombination, not absent B cells. This internal inconsistency makes the item contradictory (C). The other options are less plausible: BTK deficiency explains absent B cells but lacks neurologic disease; CD40L and AICDA defects cause hyper‑IgM with normal B cells; RAG1 deficiency causes SCID with absent B cells but not cerebellar atrophy. Because the immunologic clue is erroneous, the item is medically inaccurate (major error). The explanation’s claim of ‘combined immunodeficiency (low immunoglobulins, absent B cells)’ reinforces the error. A minimal fix would replace ‘absent B cells’ with ‘normal B‑cell numbers with defective class‑switch recombination’ to align with A‑T’s true phenotype.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": false,\n\"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a 5‑year‑old with recurrent sinopulmonary infections, new‑onset ataxia, nystagmus, diffuse cerebellar atrophy, low IgG/IgA/IgM, and absent B cells. The key discriminating features are the combination of cerebellar neurodegeneration and combined immunodeficiency. The only option that explains both neurologic and immunologic findings is ATM (ataxia‑telangiectasia). However, the vignette’s statement that flow cytometry shows absent B cells is inaccurate; A‑T patients typically have normal B‑cell numbers with impaired class‑switch recombination, not absent B cells. This internal inconsistency makes the item contradictory (C). The other options are less plausible: BTK deficiency explains absent B cells but lacks neurologic disease; CD40L and AICDA defects cause hyper‑IgM with normal B cells; RAG1 deficiency causes SCID with absent B cells but not cerebellar atrophy. Because the immunologic clue is erroneous, the item is medically inaccurate (major error). The explanation’s claim of ‘combined immunodeficiency (low immunoglobulins, absent B cells)’ reinforces the error. A minimal fix would replace ‘absent B cells’ with ‘normal B‑cell numbers with defective class‑switch recombination’ to align with A‑T’s true phenotype.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-009", "question": "A 55-year-old man with alcoholic cirrhosis presents with hepatic encephalopathy refractory to lactulose and rifaximin. He has recurrent episodes requiring hospitalization every 2-3 weeks. Transjugular intrahepatic portosystemic shunt (TIPS) is not an option due to severe pulmonary hypertension. Which of the following interventions has the strongest evidence for reducing recurrent hepatic encephalopathy in this patient?", "options": ["Daily polyethylene glycol 3350 17 g", "Empirical vancomycin 125 mg four times daily", "Oral L-ornithine L-aspartate 6 g three times daily", "Sodium benzoate 5 g twice daily", "Branch-chain amino acid supplementation three times daily"], "answer": "A", "answer_index": 0, "explanation": "Polyethylene glycol has been shown in randomized trials to be more effective than lactulose for acute hepatic encephalopathy and may reduce recurrence by more effectively clearing ammonia-producing bacteria from the gut. Vancomycin has similar efficacy to rifaximin but risk of resistance. L-ornithine L-aspartate has modest benefit as adjunct only. Sodium benzoate is second-line. Branch-chain amino acids improve nutrition but not specifically encephalopathy recurrence.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: K (Miskeyed). The vignette seeks the intervention with strongest evidence to reduce *recurrent* hepatic encephalopathy (HE) in a patient already on lactulose and rifaximin. Polyethylene glycol (PEG) has robust randomized data for *acute* HE resolution but no established evidence for chronic recurrence prevention. The rationale misattributes a bacterial clearance mechanism to PEG and incorrectly extends acute-treatment data to prophylaxis. Vancomycin (B) has documented efficacy for HE (though limited by resistance concerns), and L-ornithine L-aspartate (C) is recognized as an adjunct in some guidelines, but none of the options represent a well-evidenced choice for recurrence prevention. Consequently, the keyed answer (A) cannot be defended as best. Medical accuracy: The rationale contains major factual errors regarding PEG's mechanism and misrepresents evidence strength, constituting a significant inaccuracy that would mislead learners. Minimal fix: Revise the key to an option with the most plausible evidence (e.g., vancomycin) or reframe the question to address acute HE management where PEG is appropriately supported.\",\"medical_accuracy_score\":2,\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). The vignette seeks the intervention with strongest evidence to reduce *recurrent* hepatic encephalopathy (HE) in a patient already on lactulose and rifaximin. Polyethylene glycol (PEG) has robust randomized data for *acute* HE resolution but no established evidence for chronic recurrence prevention. The rationale misattributes a bacterial clearance mechanism to PEG and incorrectly extends acute-treatment data to prophylaxis. Vancomycin (B) has documented efficacy for HE (though limited by resistance concerns), and L-ornithine L-aspartate (C) is recognized as an adjunct in some guidelines, but none of the options represent a well-evidenced choice for recurrence prevention. Consequently, the keyed answer (A) cannot be defended as best. Medical accuracy: The rationale contains major factual errors regarding PEG's mechanism and misrepresents evidence strength, constituting a significant inaccuracy that would mislead learners. Minimal fix: Revise the key to an option with the most plausible evidence (e.g., vancomycin) or reframe the question to address acute HE management where PEG is appropriately supported.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-010", "question": "A 34-year-old woman with metastatic HER2-positive breast cancer on trastuzumab, pertuzumab, and docetaxel presents with acute decompensated heart failure. Echocardiography shows global hypokinesis with LVEF 20%, markedly reduced from baseline 55%. Which of the following biomarkers would be most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity?", "options": ["Elevated serum troponin I with normal NT-proBNP", "Markedly elevated NT-proBNP with normal troponin", "Elevated soluble ST2 with normal galectin-3", "Increased urinary 8-hydroxy-2'-deoxyguanosine", "Elevated growth differentiation factor-15 (GDF-15)"], "answer": "A", "answer_index": 0, "explanation": "Trastuzumab-induced cardiotoxicity typically presents with elevated troponin (indicating myocyte injury) but relatively preserved NT-proBNP (less volume overload/stretch), reflecting its mechanism of reversible HER2 receptor blockade without direct cellular damage. Anthracycline toxicity shows both elevated troponin and markedly elevated NT-proBNP due to irreversible cellular damage. ST2 and galectin-3 are fibrosis markers not specific to this distinction. 8-OHdG is oxidative stress marker. GDF-15 is elevated in various cardiac conditions.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"The vignette asks for a biomarker pattern that best distinguishes trastuzumab‑induced cardiomyopathy from anthracycline‑like toxicity. The keyed answer (A) proposes that trastuzumab toxicity produces an elevated troponin I with a normal NT‑proBNP, while anthracycline toxicity raises both. Among the options, A is the only one that pairs a marker of myocyte injury (troponin) with a supposedly preserved natriuretic peptide, making it the most plausible choice in the set. Options B–E describe patterns (isolated NT‑proBNP elevation, fibrosis markers, oxidative stress metabolites, or GDF‑15) that lack specificity for the stated distinction. Logically, the item offers a single best answer that fits the provided key, the options are mutually exclusive, and there is no internal inconsistency; thus the item is logically valid. Medically, however, the premise is inaccurate. In acute decompensated heart failure, NT‑proBNP is markedly elevated regardless of etiology, and trastuzumab‑related cardiotoxicity frequently raises both troponin and NT‑proBNP. No consensus supports a normal NT‑proBNP as a specific discriminator. Consequently, the answer misrepresents current understanding and could mislead learners. Minimal fix: revise the answer explanation to state that both troponin and NT‑proBNP are often elevated in trastuzumab cardiotoxicity, and no single biomarker pattern reliably distinguishes it from anthracycline damage.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette asks for a biomarker pattern that best distinguishes trastuzumab‑induced cardiomyopathy from anthracycline‑like toxicity. The keyed answer (A) proposes that trastuzumab toxicity produces an elevated troponin I with a normal NT‑proBNP, while anthracycline toxicity raises both. Among the options, A is the only one that pairs a marker of myocyte injury (troponin) with a supposedly preserved natriuretic peptide, making it the most plausible choice in the set. Options B–E describe patterns (isolated NT‑proBNP elevation, fibrosis markers, oxidative stress metabolites, or GDF‑15) that lack specificity for the stated distinction. Logically, the item offers a single best answer that fits the provided key, the options are mutually exclusive, and there is no internal inconsistency; thus the item is logically valid. Medically, however, the premise is inaccurate. In acute decompensated heart failure, NT‑proBNP is markedly elevated regardless of etiology, and trastuzumab‑related cardiotoxicity frequently raises both troponin and NT‑proBNP. No consensus supports a normal NT‑proBNP as a specific discriminator. Consequently, the answer misrepresents current understanding and could mislead learners. Minimal fix: revise the answer explanation to state that both troponin and NT‑proBNP are often elevated in trastuzumab cardiotoxicity, and no single biomarker pattern reliably distinguishes it from anthracycline damage.", "medical_accuracy_score": 2, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 2}]